Neon Therapeutics licenses neoantigen IP from Netherlands Cancer Institute
Executive Summary
The Netherlands Cancer Institute (NKI) granted Neon Therapeutics exclusive rights to intellectual property surrounding an ex vivo induction platform, which Neon will use in its drug development activities.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice